[MOL] Mesothelioma responds and NSCLC [00038] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Mesothelioma responds and NSCLC

Mesothelioma responds
Glaxo Wellcome of Research Triangle Park, N.C., said that seven of
29 patients (24%) with pleural mesothelioma had a partial response
to Navelbine (vinorelbine) in a phase-2 trial and 16 patients (55%)
achieved stable disease. Median overall survival was 11 months, and
41% of patients were alive a year after starting therapy,
investigators reported in the Dec.1 Journal of Clinical Oncology.
According to the researchers from St.Bartholomew ’s Hospital in
London, where the trial took place, other therapies for this
disease have rarely achieved response rates over 20% and have not
been shown to increase survival over supportive care. Navelbine is
approved as a first-line treatment of advanced non-small-cell
lung cancer.
We invite you to take a look at our Album.                                               
  ( Very informational, good tips, Molers pictures, art work and much more....